Patient with advanced gastric cancer responds twice to the same systemic therapy

Gastrointestinal Cancer Research

Volumn 3, Issue 3, 2009, Pages 115-117

  Lagaly, Rachel ^a   Horak, Ashley ^a   Lee, Jeffrey H ^a   Mansfield, Paul F ^a   Ajani, Jaffer A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; DOCETAXEL; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ADULT; ADVANCED CANCER; ANAMNESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CASE REPORT; ENDOSCOPIC ECHOGRAPHY; FATALITY; HUMAN; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; PERITONEUM METASTASIS; POSITRON EMISSION TOMOGRAPHY; STOMACH CANCER;

EID: 77953433227     PISSN: 19347820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Jiang Y, Kimchi ET, Montero AJ, et al: Upper gastrointestinal tumors: current status and future perspectives. Expert Rev Anticancer Ther 8:975-991, 2008
2. Parkin DM, Bray F, Ferlay J, et al: Global cancer statistics, 2002. CA Cancer J Clin 55:74-108, 2005
3. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58:71-96, 2008
4. Pohl H, Welch HG: The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 97: 142-146, 2005
5. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991-4997, 2006
6. Koizumi W, Narahara H, Hara T, et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215-221, 2008